S Madsbad, T Krarup, CF Deacon, JJ … - Current Opinion in Clinical …, 2008 - journals.lww.com Recent findings: The injectable glucagon-like peptide-1 receptor agonists exenatide significantly
improves glycaemic control, with average reductions in haemoglobin A1c of about 1.0%, fasting
plasma glucose of about 1.4 mmol/l, and causes a weight loss of approximately 2-3 kg ... Cited by 25 - Related articles - All 2 versions
WA Scherbaum, A Schweizer, A Mari, PM … - Diabetes Obes …, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 19 - Related articles - All 3 versions
AJ Garber, Y Handelsman, D Einhorn, DA Bergman, ZT … - Endocrine Practice, 2008 - AACE Alan J. Garber, MD, PhD, FACE, Yehuda Handelsman, MD, FACP, FACE, Daniel Einhorn,
MD, FACP, FACE, Donald A. Bergman, MD, FACE, Zachary T. Bloomgarden, MD, FACE, Vivian
Fonseca, MD, FACE, W. Timothy Garvey, MD, James R. Gavin III, MD, PhD, George ... Cited by 15 - Related articles - All 7 versions
RE Pratley, M Gilbert - The Review of Diabetic Studies: RDS, 2008 - pubmedcentral.nih.gov Until recently, the pathogenesis of type 2 diabetes mellitus (T2DM) has been conceptualized
in terms of the predominant defects in insulin secretion and insulin action. It is now recognized
that abnormalities in other hormones also contribute to the development of ... Cited by 8 - Related articles - All 3 versions
DA D'Alessio, AM Denney, LM Hermiller, RL … - Journal of Clinical …, 2009 - Endocrine Soc Context: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type
2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent
insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). Consistent with this ... Cited by 6 - Related articles - All 5 versions
P Van der Veken, I De Meester, V Dubois, A Soroka … - Bioorganic & medicinal …, 2008 - Elsevier The aim of this study was to evaluate a structurally diverse library of dipeptide-derived
compounds, in order to identify possible leads for the development of inhibitors with maximal
affinity and selectivity for DPP 8 and 9. The concept of developing substrate-inspired, ... Cited by 4 - Related articles - All 4 versions
S Mudaliar, RR Henry - European Journal of Internal Medicine, 2009 - Elsevier Impaired insulin secretion plays a major role in the pathogenesis of type 2 diabetes mellitus,
and progressive loss of β-cell function is a pathophysiologic hallmark of type 2 diabetes. Recent
science has elaborated on the role of the incretin hormones on β-cell function and insulin ... Cited by 3 - Related articles - All 38 versions
B Ahren, A Schweizer, S Dejager, BE Dunning, … - Journal of Clinical …, 2009 - Endocrine Soc Context: Dipeptidyl peptidase-4 inhibitors act by increasing plasma levels of glucagon-like
peptide-1 and suppressing excessive glucagon secretion in patients with type 2 diabetes.
However, their effects on the glucagon response to hypoglycemia are not established. Cited by 6 - Related articles - All 3 versions
SE Kahn, DB Carr, MV Faulenbach, KM … - Diabetes, Obesity and …, 2008 - interscience.wiley.com A characteristic and dominant feature of type 2 diabetes is a reduction in β-cell function that is
associated with a decrease in β-cell volume. A decline in the first-phase insulin response following
intravenous glucose administration can be demonstrated as the fasting glucose ... Cited by 2 - Related articles - All 2 versions
S Halimi, A Schweizer, B Minic, J Foley, … - Vascular Health and …, 2008 - pubmedcentral.nih.gov Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), orally
active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily by enhancing
pancreatic (α and β) islet function. Thus vildagliptin has been shown both to improve ... Cited by 2 - Related articles - All 7 versions
